<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02716129</url>
  </required_header>
  <id_info>
    <org_study_id>IRB0000871235</org_study_id>
    <nct_id>NCT02716129</nct_id>
  </id_info>
  <brief_title>The Effect of Adding Nalbuphine to Intrathecal Morphine on Analgesic Efficacy and Side Effects After Cesarean Section</brief_title>
  <official_title>Post-cesarean Section Analgesic Potency and Side Effects of Intrathecal Morphine and Nalbuphine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abdelrady S Ibrahim, MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assiut University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary endpoint of this study is to investigate the effect of adding nalbuphine to
      intrathecal morphine on quality of postoperative analgesia and Morphine related side effects
      post- cesarean delivery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will be performed in Assiut University Hospitals, after obtaining approval from the
      local ethics committee and written informed patient consent. All patients will have a
      peripheral IV cannula 18 G inserted; standard non-invasive monitors will be applied. All the
      patients will be preloaded with 10 ml/kg Ringer's lactate solution intravenous. Intrathecal
      block under strict aseptic conditions will be performed in sitting position at L3-4 or L4-5
      inter-spinous space with 25G pencil-point spinal needle. All patients will receive
      intrathecal 10 mg of 0.5% hyperbaric bupivacaine.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 2016</start_date>
  <completion_date type="Actual">October 2017</completion_date>
  <primary_completion_date type="Actual">October 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Postoperative pain</measure>
    <time_frame>24 hours</time_frame>
    <description>Visual Analogue Score</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of postoperative itching</measure>
    <time_frame>24 hours</time_frame>
    <description>Visual Analogue Score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of participants with incidence of postoperative nausea</measure>
    <time_frame>24 hours</time_frame>
    <description>Patients number</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of participants with incidence of postoperative vomiting</measure>
    <time_frame>24 hours</time_frame>
    <description>Patients number</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of participants with incidence of postoperative postdural puncture headache</measure>
    <time_frame>24 hours</time_frame>
    <description>Patients number</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of participants with incidence of postoperative respiratory depression</measure>
    <time_frame>24 hours</time_frame>
    <description>Patients number</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Postoperative Pain</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Morphine group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Morphine plus Nalbuphine group</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Morphine</intervention_name>
    <description>38 patients of this group will receive 10 mg of 0.5% hyperbaric bupivacaine (Buvanest Spinal 0.5% Heavy) with 0.2 mg morphine (Infumorph - Injection 10 mg/mL) in 0.5 ml volume (total volume 2.5 mL). Patients will be preloaded with 10 ml/kg Ringer's lactate solution intravenous.</description>
    <arm_group_label>Group 1</arm_group_label>
    <other_name>Infumorph</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Morphine plus Nalbuphine</intervention_name>
    <description>39 patients of this group will receive 10 mg of 0.5% hyperbaric bupivacaine (Buvanest Spinal 0.5% Heavy) with 0.5 mg morphine (Infumorph - Injection 10 mg/mL) plus 0.2 mg nalbuphine (NALUFIN 20MG/ML AMP) in 0.5 ml volume (total volume 2.5 mL). Patients will be preloaded with 10 ml/kg Ringer's lactate solution intravenous.</description>
    <arm_group_label>Group 2</arm_group_label>
    <other_name>Infumorph and NALUFIN</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female patients

          -  age between 16 to 40 years

          -  ASA physical status I - II

        Exclusion Criteria:

          -  Infection at the site of injection.

          -  Coagulopathy or other bleeding diathesis.

          -  Preexisting neurologic deficits.

          -  History of hypersensitivity to any of the given the drugs.

          -  Inability to communicate with the investigator and the hospital staff.

          -  History of chronic opioid us
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Abdelrady S Ibrahim, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistant professor of anesthesia and intensive care</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Assiut university faculty of medicine</name>
      <address>
        <city>Assiut</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <reference>
    <citation>Culebras X, Gaggero G, Zatloukal J, Kern C, Marti RA. Advantages of intrathecal nalbuphine, compared with intrathecal morphine, after cesarean delivery: an evaluation of postoperative analgesia and adverse effects. Anesth Analg. 2000 Sep;91(3):601-5.</citation>
    <PMID>10960384</PMID>
  </reference>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 15, 2016</study_first_submitted>
  <study_first_submitted_qc>March 22, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 23, 2016</study_first_posted>
  <last_update_submitted>December 24, 2017</last_update_submitted>
  <last_update_submitted_qc>December 24, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 27, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Assiut University</investigator_affiliation>
    <investigator_full_name>Abdelrady S Ibrahim, MD</investigator_full_name>
    <investigator_title>Assistant professor of Anesthesia and ICU</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Morphine</mesh_term>
    <mesh_term>Nalbuphine</mesh_term>
    <mesh_term>Analgesics</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

